DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07249372
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • DRP-104 — DRUG
    DRP-104 will be administered subcutaneously (subQ) at a dose of 145mg twice a week (BIW) on a continuous schedule. Once the first dose is administered, the second weekly dose is to be administered 3 days after the first dose with a four-day rest period before the next week of therapy (example, Monday/Thursday or Tuesday/Friday).

Study Details

This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.

Key Dates

Start date
Jan 14, 2026
Status verified
May 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NFE2L2/KEAP1-Altered NSCLC
    Participants with NFE2L2/KEAP1-altered non-small cell lung cancer previously treated with chemotherapy and immunotherapy will receive subcutaneous DRP-104 (BIW) on a 21-day cycle with no rest period between cycles but with at least 3 days between injections.

Primary Outcome Measure

Overall Response Rate (ORR) [ Time Frame: Up to Year 2 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Columbia UniversityNew YorkNew York10032
Brian S Henick, MD (PRINCIPAL_INVESTIGATOR)
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Columbia University· New York, NYNYU Langone Health· New York, NY

Related Studies